Thermo Fisher Scientific Inc. priced an underwritten public offering of 8,771,930 common shares at $171 per share.

The company, which expects gross proceeds of about $1.5 billion from the offering, granted the underwriters a 30-day option to purchase up to an additional 1,315,789 common shares.

The share issuance is expected to close Aug. 11.

Thermo Fisher plans to use all the net proceeds of the offering to fund a portion of the consideration payable for its acquisition of Patheon N.V., including the repayment of Patheon's debt to be assumed by Thermo Fisher.

Goldman Sachs & Co. LLC is acting as lead book-running manager, while BofA Merrill Lynch and Citigroup are acting as joint book-running managers for the offering.